Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-11

  Gonnermann, Daniel ^a   Oberg, Hans Heinrich ^a   Kellner, Christian ^a   Peipp, Matthias ^a   Sebens, Susanne ^a   Kabelitz, Dieter ^a   Wesch, Daniela ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cox 2; Cytotoxicity; Gammadelta T lymphocytes; Human; Pancreatic ductal adenocarcinoma; PGE2

Indexed keywords

ADALIMUMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INFLIXIMAB; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; COCULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; WESTERN BLOTTING;

EID: 84954513347     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.988460     Document Type: Article

References (45)

1. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007; 26:525-34; PMID:17763971; http://dx.doi.org/10.1007/s10555-007-9096-5
2. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23:144-50; PMID:11864843; http://dx.doi.org/10.1016/S1471-4906(01)02154-8
3. Merati K, Said SM, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarci-noma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001; 24:447-52; PMID:11586094; http://dx.doi.org/10.1097/00000421-200110000-00007
4. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59:4356-62; PMID:10485483
5. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999; 26:69-76; PMID:10597402; http://dx.doi.org/10.1007/BF02781733
6. Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol 2012; 90:579-86; PMID:21946663; http://dx.doi.org/10.1038/icb.2011.75
7. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglan-din E2 by tumor cells in vivo. Cancer Res 2008; 68:7520-9; PMID:18794140; http://dx.doi.org/10.1158/0008-5472.CAN-08-1060
8. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubi-nett SM. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175:1483-90; PMID:16034085; http://dx.doi.org/10.4049/jimmunol.175.3.1483
9. Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournie JJ, Poupot R. A regulatory cross-talk between Vγ9Vd2 T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39:752-62; PMID:19197941; http://dx.doi.org/10.1002/eji.200838812
10. Kabashima-Niibe A, Higuchi H, Takaishi H, Masugi Y, Matsuzaki Y, Mabuchi Y, Funakoshi S, Adachi M, Hamamoto Y, Kawachi S, et al. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Cancer Sci 2013; 104:157-64; PMID:23121112; http://dx.doi.org/10.1111/cas.12059
11. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramo-chi H, Tanaka K, et al. Assessment of celecoxib phar-macodynamics in pancreatic cancer. Mol Cancer Ther 2006; 5:3240-7; PMID:17172427; http://dx.doi.org/10.1158/1535-7163.MCT-06-0565
12. Vosooghi M, Amini M. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014; 9:255-67; PMID:24483845; http://dx.doi.org/10.1517/17460441.2014.883377
13. Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY. Selective inhibition ofcyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008; 215:149-57; PMID:18577844; http://dx.doi.org/10.1620/tjem.215.149
14. Dragovich T, Burris H, III, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarci-noma: results of a phase II trial. Am J Clin Oncol 2008; 31:157-62; PMID:18391600; http://dx.doi.org/10.1097/COC.0b013e31815878c9
15. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and cele-coxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010; 44:286-8; PMID:20216081; http://dx.doi.org/10.1097/MCG.0b013e3181cda097
16. Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett 2014; 343:147-55; PMID:24141189; http://dx.doi.org/10.1016Zj.canlet.2013.09.039
17. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
18. Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Rocken C, Becker T, Vogel I, et al. Novel bispecific antibodies increase gd T-cell cytotoxicity against pancreatic cancer cells. Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/0008-5472.CAN-13-0675
19. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gd T cells. Cancer Res 2009; 69:87107; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602
20. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442:444-52; PMID:12692724
21. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation ofprostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275:32783-92; PMID:10869354; http://dx.doi.org/10.1074/jbc.M003505200
22. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 2011; 100:1987-95; PMID:21374628; http://dx.doi.org/10.1002/jps.22393
23. Pietschmann K, Beetz S, Welte S, Martens I, Gruen J, Oberg HH, Wesch D, Kabelitz D. Toll-like receptor expression and function in subsets ofhuman gd T lymphocytes. Scand J Immunol 2009; 70:245-55; PMID:19703014; http://dx.doi.org/10.1111/j.1365-3083.2009.02290.x
24. Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect ofTLR3 ligand poly(I:C) on human gd T lymphocytes. J Immunol 2006; 176:1348-54; PMID:16424161; http://dx.doi.org/10.4049/jimmunol.176.3.1348
25. Helm O, Mennrich R, Petrick D, Goebel L, FreitagWolf S, Roder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, et al. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. PLoS One 2014; 9:e94357; PMID:24797069; http://dx.doi.org/10.1371/journal.pone.0094357
26. Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R. PGE2 inhibits natural killer and gd T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010; 80:838-45; PMID:20470757; http://dx.doi.org/10.1016/j.bcp.2010.05.002
27. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60:4705-8; PMID:10987272
28. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997; 49:15-9; PMID:9249646
29. Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, et al. Cell intrinsic role ofCOX-2 in pancreatic cancer development. Mol Cancer Ther 2012; 11:2127-37; PMID:22784710; http://dx.doi.org/10.1158/1535-7163.MCT-12-0342
30. Alfranca A, Iniguez MA, Fresno M, Redondo JM. Pros-tanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 2006; 70:446-56; PMID:16458868; http://dx.doi.org/10.1016/j.cardiores.2005.12.020
31. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev1999; 79:1193-226; PMID:10508233
32. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 2005; 4:1263-9; PMID:16319525; http://dx.doi.org/10.4161/cbt.4.11.2138
33. Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 2002; 32:3358-65; PMID:12432566; http://dx.doi.org/10.1002/1521-4141(200212)32:12%3c3358::AID-IMMU3358%3e3.0.CO;2-Q
34. Samten B, Howard ST, Weis SE, Wu S, Shams H, Townsend JC, Safi H, Barnes PF. Cyclic AMP response element-binding protein positively regulates production of IFN-g by T cells in response to a microbial pathogen. J Immunol 2005; 174:6357-63; PMID:15879136; http://dx.doi.org/10.4049/jimmunol.174.10.6357
35. Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade ofthe suppressive effects ofprostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 2011; 60:111-22; PMID:20960188; http://dx.doi.org/10.1007/s00262-010-0924-z
36. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K. Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem 2003; 278:17597-600; PMID:12665526; http://dx.doi.org/10.1074/jbc.C300077200
37. Nishigaki N, Negishi M, Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inac-tivation ofthe agonist. Mol Pharmacol 1996; 50:10317; PMID:8863851
38. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005; 48:352-9; PMID:15850674; http://dx.doi.org/10.1016/j.brainresrev.2004.12.024
39. Yamaguchi K, Nakano K, Nagai E, Chijiiwa K, Kinoshita M, Ohta M, Tanaka M. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepatogastroenterology 2005; 52:713-8; PMID:15966189
40. Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 2014; 143:19-31; PMID:24281828; http://dx.doi.org/10.1007/s10549-013-2779-4
41. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013; 2:e22647; PMID:23482441; http://dx.doi.org/10.4161/onci.22647
42. Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, Li W, Inoue Y, Ackermann K, Shirota H, et al. A novel antagonist of the prostaglandin E(2) EP (4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol 2010; 160:292-310; PMID:20423341; http://dx.doi.org/10.1111/j.1476-5381.2010.00647.x
43. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Die-derich M. The role ofcyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010; 2010:215158; PMID:20339581; http://dx.doi.org/10.1155/2010/215158
44. Lipton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park) 2004; 18:435; PMID:15685834
45. Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY. Selective inhibition ofcyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008; 215:149-57; PMID:18577844; http://dx.doi.org/10.1620/tjem.215.149